Management of chronic myeloid leukemia in blast crisis (Q38392682)

2 September 2017

1 reference

title

Management of chronic myeloid leukemia in blast crisis (English)

1 reference

2 September 2017

main subject

chronic myeloid leukemia

0 references

author name string

S Saußele

series ordinal

1

1 reference

2 September 2017

Richard T Silver

series ordinal

2

1 reference

2 September 2017

publication date

27 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

94 Suppl 2

1 reference

2 September 2017

page(s)

S159-65

1 reference

Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Phase distribution of chronic myeloid leukemia in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

How I treat CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

The blast phase of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

The Biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Chronic myeloid leukaemia as a model of disease evolution in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Treatment of chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with ima

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

The EBMT activity survey: 1990-2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Advances in immunotherapy of chronic myeloid leukemia CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2324-0

10.1007/S00277-015-2324-0

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference